Last reviewed · How we verify

Iron Sucrose Supplement

Papageorgiou General Hospital · FDA-approved active Small molecule

Iron sucrose provides bioavailable iron that is absorbed and incorporated into hemoglobin and other iron-dependent proteins to treat iron deficiency.

Iron sucrose provides bioavailable iron that is absorbed and incorporated into hemoglobin and other iron-dependent proteins to treat iron deficiency. Used for Iron deficiency anemia in patients with chronic kidney disease, Iron deficiency anemia in patients on hemodialysis or peritoneal dialysis, Iron deficiency anemia in non-dialysis chronic kidney disease patients.

At a glance

Generic nameIron Sucrose Supplement
SponsorPapageorgiou General Hospital
Drug classIron supplement
ModalitySmall molecule
Therapeutic areaHematology
PhaseFDA-approved

Mechanism of action

Iron sucrose is a stable complex of iron (III) hydroxide with sucrose that delivers iron for erythropoiesis and cellular function. After administration, the iron is released and transported via transferrin to bone marrow for incorporation into hemoglobin synthesis, and to tissues for myoglobin and iron-dependent enzyme production. This replenishes depleted iron stores and corrects iron deficiency anemia.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: